comparemela.com

Latest Breaking News On - Avistone biotechnology - Page 4 : comparemela.com

Why Is Cancer Firm Apollomics (APLM) Stock Trading Higher Today? - Apollomics (NASDAQ:APLM)

Apollomics Inc's (NASDAQ: APLM) partner in China, Avistone Biotechnology Co.

Hong kongNational medical products administrationAvistone biotechnology coApollomics incAvistone biotechnologyNew drug application

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

FOSTER CITY, Calif., Oct. 26, 2023 Apollomics Inc. , today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM with.

United statesGuo liang yuPeter vozzoSean leousEuropean society of medical oncology congressNational medical products administrationApollomics incVeneto institute of oncologySecurities exchangeVeneto instituteEuropean societyMedical oncology congressPartial responseChief executive officerNew drug applicationAvistone biotechnology

Apollomics Inc Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%

Apollomics Inc. announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical Oncology Congress 2023, being held in Madrid,.

Avistone biotechnology ltdApollomics incEuropean society of medical oncology congressPearl biotechnology ltdEuropean societyMedical oncology congressApollomic chinaAvistone biotechnologyBeijing pearl biotechnology ltd

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

FOSTER CITY, Calif., Oct. 23, 2023 Apollomics Inc. , today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Medical.

United statesGuo liang yuSean leousPeter vozzoPearl biotechnology ltdEuropean society of medical oncology congressSecurities exchangeApollomics incAvistone biotechnology ltdEuropean societyMedical oncology congressNon small cell lung cancerChief executive officerApollomic chinaAvistone biotechnologyBeijing pearl biotechnology ltd

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation

FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) Apollomics Inc. (Nasdaq: APLM ) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical

United statesGuo liang yuSean leousPeter vozzoApollomics incEuropean society of medical oncology congressAvistone biotechnology ltdPearl biotechnology ltdSecurities exchangeEuropean societyMedical oncology congressNon small cell lung cancerChief executive officerApollomic chinaAvistone biotechnologyBeijing pearl biotechnology ltd

vimarsana © 2020. All Rights Reserved.